NAFLD — Genetic-specific Effects of Fructose on Liver Lipogenesis
Citation(s)
Akhavan T, Anderson GH Effects of glucose-to-fructose ratios in solutions on subjective satiety, food intake, and satiety hormones in young men. Am J Clin Nutr. 2007 Nov;86(5):1354-63. doi: 10.1093/ajcn/86.5.1354.
Alwahsh SM, Gebhardt R Dietary fructose as a risk factor for non-alcoholic fatty liver disease (NAFLD). Arch Toxicol. 2017 Apr;91(4):1545-1563. doi: 10.1007/s00204-016-1892-7. Epub 2016 Dec 19.
Awai HI, Newton KP, Sirlin CB, Behling C, Schwimmer JB Evidence and recommendations for imaging liver fat in children, based on systematic review. Clin Gastroenterol Hepatol. 2014 May;12(5):765-73. doi: 10.1016/j.cgh.2013.09.050. Epub 2013 Sep 30.
Basaranoglu M, Basaranoglu G, Bugianesi E Carbohydrate intake and nonalcoholic fatty liver disease: fructose as a weapon of mass destruction. Hepatobiliary Surg Nutr. 2015 Apr;4(2):109-16. doi: 10.3978/j.issn.2304-3881.2014.11.05.
Bonder A, Afdhal N Utilization of FibroScan in clinical practice. Curr Gastroenterol Rep. 2014 Feb;16(2):372. doi: 10.1007/s11894-014-0372-6.
Faeh D, Minehira K, Schwarz JM, Periasamy R, Park S, Tappy L Effect of fructose overfeeding and fish oil administration on hepatic de novo lipogenesis and insulin sensitivity in healthy men. Diabetes. 2005 Jul;54(7):1907-13. doi: 10.2337/diabetes.54.7.1907. Erratum In: Diabetes. 2006 Feb;55(2):563. Periasami, Raj [corrected to Periasamy, Raj]; Seongsu, Park [corrected to Park, Seongsu].
Moore JB, Gunn PJ, Fielding BA The role of dietary sugars and de novo lipogenesis in non-alcoholic fatty liver disease. Nutrients. 2014 Dec 10;6(12):5679-703. doi: 10.3390/nu6125679.
Santoro N, Caprio S, Pierpont B, Van Name M, Savoye M, Parks EJ Hepatic De Novo Lipogenesis in Obese Youth Is Modulated by a Common Variant in the GCKR Gene. J Clin Endocrinol Metab. 2015 Aug;100(8):E1125-32. doi: 10.1210/jc.2015-1587. Epub 2015 Jun 4. Erratum In: J Clin Endocrinol Metab. 2020 Jan 2;105(2):
Shin HJ, Kim HG, Kim MJ, Koh H, Kim HY, Roh YH, Lee MJ Normal range of hepatic fat fraction on dual- and triple-echo fat quantification MR in children. PLoS One. 2015 Feb 6;10(2):e0117480. doi: 10.1371/journal.pone.0117480. eCollection 2015.
Ter Horst KW, Schene MR, Holman R, Romijn JA, Serlie MJ Effect of fructose consumption on insulin sensitivity in nondiabetic subjects: a systematic review and meta-analysis of diet-intervention trials. Am J Clin Nutr. 2016 Dec;104(6):1562-1576. doi: 10.3945/ajcn.116.137786. Epub 2016 Nov 9.
Ventura EE, Davis JN, Goran MI Sugar content of popular sweetened beverages based on objective laboratory analysis: focus on fructose content. Obesity (Silver Spring). 2011 Apr;19(4):868-74. doi: 10.1038/oby.2010.255. Epub 2010 Oct 14.
Vos MB, Kimmons JE, Gillespie C, Welsh J, Blanck HM Dietary fructose consumption among US children and adults: the Third National Health and Nutrition Examination Survey. Medscape J Med. 2008 Jul 9;10(7):160.
Zhou Y, Wei F, Fan Y High serum uric acid and risk of nonalcoholic fatty liver disease: A systematic review and meta-analysis. Clin Biochem. 2016 May;49(7-8):636-42. doi: 10.1016/j.clinbiochem.2015.12.010. Epub 2015 Dec 29.
Genetic-specific Effects of Fructose on Liver Lipogenesis
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.